Fairmount Healthcare Fund II L.P.
CIK 1769651 · last filed 2026-09-10
Fairmount Healthcare Fund II L.P. is a corporate insider who has filed 11 SEC Form 4 insider transactions across 6 companies since 2023. The most recent filing, for KRSA, was dated Sep 10, 2026. Across all open-market trades the lifetime net is +$332.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $159.7M across reported positions. The firm reports its address in West Conshohocken, PA. 54 SEC filings were submitted jointly with Fairmount Funds Management LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 400
WEST CONSHOHOCKEN, PA 19428
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRSA | Director | — | — | — | $0 | 1 | 2026-09-10 |
| ORKA | Director | 638,614 | $90.33 | $57.69M | $0 | 2 | 2026-06-03 |
| ZBIO | Director | 2,359,025 | $27.24 | $64.26M | $32.40M | 2 | 2026-04-01 |
| DMRA | Director | — | $21.26 | — | $0 | 1 | 2026-03-25 |
| SYRE | Director | 406,038 | $92.91 | $37.72M | $0 | 3 | 2025-06-02 |
| Apogee Therapeutics, Inc. (APGE) Delisted | Director | 0 | $135.07 | $0 | $300.00M | 2 | 2024-01-31 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-10 | KRSA | Grant (A) | — | $0 | EDGAR |
| 2026-06-03 | ORKA | Grant (A) | — | $0 | EDGAR |
| 2026-04-01 | ZBIO | Buy (P) | +600,000 | $12.00M | EDGAR |
| 2026-03-25 | DMRA | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2024-09-17 | ZBIO | Mixed | +6,419,564 | $20.40M | EDGAR |
| 2024-09-13 | ORKA | Grant (A) | +1,100,000 | $25.30M | EDGAR |
| 2024-04-25 | SYRE | Exer (M) | +14,558,720 | $0 | EDGAR |
| 2024-01-31 | Apogee Therapeutics, Inc. (APGE) Delisted | Other (J) | −4,741,182 | $0 | EDGAR |
| 2023-12-11 | SYRE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.